Lebensztejn DM - Search Results

1

Serum concentration of fatty acids in children with obesity and nonalcoholic fatty liver disease.

Kopiczko N, Bobrus-Chociej A, Harasim-Symbor E, Tarasów E, Wojtkowska M, Chabowski A, Lebensztejn DM. Kopiczko N, et al. Among authors: lebensztejn dm. Nutrition. 2022 Feb;94:111541. doi: 10.1016/j.nut.2021.111541. Epub 2021 Nov 15. Nutrition. 2022. PMID: 34974284

2

Retinol binding protein-4 as a serum biomarker of intrahepatic lipid content in obese children--preliminary report.

Romanowska A, Lebensztejn DM, Skiba E, Tarasów E, Kaczmarski M. Romanowska A, et al. Among authors: lebensztejn dm. Acta Biochim Pol. 2011;58(1):35-8. Epub 2011 Mar 7. Acta Biochim Pol. 2011. PMID: 21383997

3

Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease.

Lebensztejn DM, Wierzbicka A, Socha P, Pronicki M, Skiba E, Werpachowska I, Kaczmarski M. Lebensztejn DM, et al. Acta Biochim Pol. 2011;58(4):563-6. Epub 2011 Dec 3. Acta Biochim Pol. 2011. PMID: 22140659

4

[Frequency and causes for hospitalization of children with cholelithiasis - own observations].

Uścinowicz M, Kowalczuk-Krystoń M, Bobrus-Chociej A, Lebensztejn D, Kaczmarski M. Uścinowicz M, et al. Med Wieku Rozwoj. 2011 Oct-Dec;15(4):467-71. Med Wieku Rozwoj. 2011. PMID: 22516703 Polish.

5

Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial.

Janczyk W, Socha P, Lebensztejn D, Wierzbicka A, Mazur A, Neuhoff-Murawska J, Matusik P. Janczyk W, et al. BMC Pediatr. 2013 May 23;13:85. doi: 10.1186/1471-2431-13-85. BMC Pediatr. 2013. PMID: 23702094 Free PMC article. Clinical Trial.

6

Serum fetuin A concentration is elevated in children with non-alcoholic fatty liver disease.

Lebensztejn DM, Białokoz-Kalinowska I, Kłusek-Oksiuta M, Tarasów E, Wojtkowska M, Kaczmarski M. Lebensztejn DM, et al. Adv Med Sci. 2014 Mar;59(1):81-4. doi: 10.1016/j.advms.2013.08.003. Epub 2014 Mar 22. Adv Med Sci. 2014. PMID: 24797980

7

Hepatotoxicity caused by montelukast in a paediatric patient.

Lebensztejn DM, Bobrus-Chociej A, Kłusek M, Uscinowicz M, Lotowska J, Sobaniec-Lotowska M, Kaczmarski M. Lebensztejn DM, et al. Prz Gastroenterol. 2014;9(2):121-3. doi: 10.5114/pg.2014.42509. Epub 2014 May 5. Prz Gastroenterol. 2014. PMID: 25061494 Free PMC article.

8

Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.

Janczyk W, Lebensztejn D, Wierzbicka-Rucińska A, Mazur A, Neuhoff-Murawska J, Matusik P, Socha P. Janczyk W, et al. J Pediatr. 2015 Jun;166(6):1358-63.e1-3. doi: 10.1016/j.jpeds.2015.01.056. Epub 2015 Mar 11. J Pediatr. 2015. PMID: 25771388 Clinical Trial.

9

Hepatokines and non-alcoholic fatty liver disease.

Lebensztejn DM, Flisiak-Jackiewicz M, Białokoz-Kalinowska I, Bobrus-Chociej A, Kowalska I. Lebensztejn DM, et al. Acta Biochim Pol. 2016;63(3):459-67. doi: 10.18388/abp.2016_1252. Epub 2016 Jun 6. Acta Biochim Pol. 2016. PMID: 27262842 Free article. Review.

10

Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.

Wasilewska N, Bobrus-Chociej A, Harasim-Symbor E, Tarasów E, Wojtkowska M, Chabowski A, Lebensztejn DM. Wasilewska N, et al. Among authors: lebensztejn dm. Lipids Health Dis. 2018 Sep 12;17(1):216. doi: 10.1186/s12944-018-0855-9. Lipids Health Dis. 2018. PMID: 30208901 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

123 results

Search Page

Filters